CR10684A - Metodos para administrar agentes hipoglicemicos de larga duracion - Google Patents

Metodos para administrar agentes hipoglicemicos de larga duracion

Info

Publication number
CR10684A
CR10684A CR10684A CR10684A CR10684A CR 10684 A CR10684 A CR 10684A CR 10684 A CR10684 A CR 10684A CR 10684 A CR10684 A CR 10684A CR 10684 A CR10684 A CR 10684A
Authority
CR
Costa Rica
Prior art keywords
hypoglycemic agents
methods
managing long
term hypoglycemic
term
Prior art date
Application number
CR10684A
Other languages
English (en)
Inventor
a bush Mark
E Matthews Jessica
e walker Susan
Original Assignee
Smithkline Beecham Corp
Koppert Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Koppert Bv filed Critical Smithkline Beecham Corp
Publication of CR10684A publication Critical patent/CR10684A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion se refiere a metodos y composiciones farmaceuticas relacionadas con administrar agentes hipoglicemicos y/o agonistas de GLP-1 en donde la media de los valores de concentracion maxima en el plasma (Cmax) y/o area bajo la curva (AUC) del agente hipogrlicemicos son incrementados y/o sostenidos.
CR10684A 2006-09-13 2009-03-23 Metodos para administrar agentes hipoglicemicos de larga duracion CR10684A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82547206P 2006-09-13 2006-09-13
US86839106P 2006-12-04 2006-12-04

Publications (1)

Publication Number Publication Date
CR10684A true CR10684A (es) 2009-04-28

Family

ID=39184534

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10684A CR10684A (es) 2006-09-13 2009-03-23 Metodos para administrar agentes hipoglicemicos de larga duracion

Country Status (25)

Country Link
US (3) US8338369B2 (es)
EP (1) EP2073834B1 (es)
JP (2) JP5524620B2 (es)
KR (1) KR101472601B1 (es)
CN (1) CN103705911A (es)
AR (1) AR062775A1 (es)
AU (1) AU2007296499C1 (es)
BR (1) BRPI0716765A8 (es)
CA (1) CA2662622C (es)
CL (1) CL2007002634A1 (es)
CR (1) CR10684A (es)
EA (1) EA017159B1 (es)
ES (1) ES2442869T3 (es)
IL (1) IL197448A (es)
JO (1) JO2945B1 (es)
MA (1) MA30768B1 (es)
MX (1) MX2009002863A (es)
MY (1) MY149911A (es)
NO (1) NO20091266L (es)
NZ (1) NZ575419A (es)
PE (2) PE20080840A1 (es)
SG (2) SG174770A1 (es)
TW (1) TWI430806B (es)
WO (1) WO2008033888A2 (es)
ZA (1) ZA200901548B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE029798T2 (en) 2005-11-04 2017-03-28 Glaxosmithkline Llc Methods of administering hypoglycemic agents
DK2373681T3 (en) * 2008-12-10 2017-04-24 Glaxosmithkline Llc PHARMACEUTICAL COMPOSITIONS OF ALBIGLUTID
JP2013525491A (ja) 2010-05-04 2013-06-20 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 心血管障害を治療または予防し心血管保護を提供する方法
PL2651398T3 (pl) 2010-12-16 2018-05-30 Novo Nordisk A/S Stałe kompozycje zawierające agonistę GLP-1 i sól kwasu N-(8-(2-hydroksybenzoilo)amino)kaprylowego
DK2696687T3 (en) 2011-04-12 2017-02-06 Novo Nordisk As Double-acylated GLP-1 derivatives
HUE042757T2 (hu) 2012-03-22 2019-07-29 Novo Nordisk As Szállító szert tartalmazó készítmények és elõállításuk
EP4324475A1 (en) 2012-03-22 2024-02-21 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
JP6517690B2 (ja) 2012-06-20 2019-05-22 ノヴォ ノルディスク アー／エス ペプチド及び送達剤を含む錠剤製剤
KR20210086717A (ko) * 2013-05-02 2021-07-08 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여
AR096440A1 (es) 2013-05-28 2015-12-30 Takeda Pharmaceuticals Co Compuesto peptídico agonista del receptor del péptido similar al glucagón tipo i (glp-1) y del péptido insulinotrópico dependiente de glucosa (gip)
EP3467106B1 (en) 2016-05-24 2025-07-09 Takeda Pharmaceutical Company Limited Peptide compound
WO2019149880A1 (en) 2018-02-02 2019-08-08 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
TW202423476A (zh) * 2021-03-23 2024-06-16 美商美國禮來大藥廠 含腸促胰島素(incretin)類似物之組合物及其用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
DE69739172D1 (de) * 1996-08-08 2009-01-29 Amylin Pharmaceuticals Inc Regulation gastrointestinaler beweglichkeit
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US6380357B2 (en) * 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
HUP0103369A3 (en) * 1998-08-28 2002-03-28 Lilly Co Eli Use of insulinotropic peptides
SI1180121T1 (en) * 1999-05-17 2004-04-30 Conjuchem, Inc. Long lasting insulinotropic peptides
US6395767B2 (en) * 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
ES2311560T3 (es) * 2000-12-07 2009-02-16 Eli Lilly And Company Proteinas de fusion glp-1.
EP2186824A3 (en) * 2000-12-13 2010-09-22 Eli Lilly & Company Chronic treatment regimen using glucagon-like insulinotropic peptides
JP2005506956A (ja) * 2001-06-01 2005-03-10 イーライ・リリー・アンド・カンパニー 長時間作用性ｇｌｐ−１製剤
CA2458371A1 (en) * 2001-08-23 2003-03-06 Eli Lilly And Company Glucagon-like peptide-1 analogs
AR036711A1 (es) 2001-10-05 2004-09-29 Bayer Corp Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
KR20040054729A (ko) 2001-10-18 2004-06-25 브리스톨-마이어스 스큅 컴퍼니 인간 글루카곤-유사-펩티드-1 모방체, 및 당뇨병 및 이와관련된 증상의 치료에 있어서 이의 용도
PT1463751E (pt) * 2001-12-21 2013-08-26 Human Genome Sciences Inc Proteínas de fusão de albumina
EP1463752A4 (en) * 2001-12-21 2005-07-13 Human Genome Sciences Inc ALBUM INFUSION PROTEINS
BR0306706A (pt) * 2002-01-08 2007-03-27 Lilly Co Eli peptìdeo glp-1 estendido, métodos de estimulação do receptor de glp-1 em um indivìduo necessitando de normalização de glicose sanguìnea, de tratamento de um indivìduo profilaticamente para diabetes independente de insulina, de redução ou de manutenção do peso corporal, de tratamento da obesidade, e de tratamento de doenças, em um indivìduo necessitando do mesmo, uso de um composto de glp-1, processo de preparação de uma formulação farmacêutica, e, formulação farmacêutica
CA2513213C (en) * 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
EP1689757B1 (en) * 2003-11-12 2014-08-27 Phenomix Corporation Heterocyclic boronic acid compounds
JP4697596B2 (ja) * 2004-01-13 2011-06-08 旭硝子株式会社 多層積層体
JP5010923B2 (ja) * 2004-02-09 2012-08-29 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド アルブミン融合蛋白質
EP1758575A1 (en) * 2004-06-11 2007-03-07 Novo Nordisk A/S Counteracting drug-induced obesity using glp-1 agonists
HUE029798T2 (en) * 2005-11-04 2017-03-28 Glaxosmithkline Llc Methods of administering hypoglycemic agents
WO2007139589A1 (en) 2006-05-26 2007-12-06 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators

Also Published As

Publication number Publication date
TWI430806B (zh) 2014-03-21
BRPI0716765A2 (pt) 2013-09-24
EP2073834A2 (en) 2009-07-01
EP2073834A4 (en) 2010-11-03
EA200970274A1 (ru) 2009-08-28
JP2014148524A (ja) 2014-08-21
AR062775A1 (es) 2008-12-03
US20100009910A1 (en) 2010-01-14
SG10201501749WA (en) 2015-05-28
CL2007002634A1 (es) 2008-05-16
CA2662622C (en) 2017-01-17
MA30768B1 (fr) 2009-10-01
PE20121528A1 (es) 2012-12-12
SG174770A1 (en) 2011-10-28
BRPI0716765A8 (pt) 2017-02-21
MX2009002863A (es) 2009-03-30
US20140066371A1 (en) 2014-03-06
MY149911A (en) 2013-10-31
AU2007296499A1 (en) 2008-03-20
KR20090059155A (ko) 2009-06-10
JP5524620B2 (ja) 2014-06-18
AU2007296499B2 (en) 2013-05-02
WO2008033888A2 (en) 2008-03-20
CN103705911A (zh) 2014-04-09
ES2442869T3 (es) 2014-02-14
TW200824706A (en) 2008-06-16
PE20080840A1 (es) 2008-08-27
EA017159B1 (ru) 2012-10-30
NZ575419A (en) 2011-11-25
IL197448A0 (en) 2011-08-01
KR101472601B1 (ko) 2014-12-15
NO20091266L (no) 2009-06-09
IL197448A (en) 2013-06-27
EP2073834B1 (en) 2013-10-23
JP2010503697A (ja) 2010-02-04
US20130005652A1 (en) 2013-01-03
US8338369B2 (en) 2012-12-25
WO2008033888A3 (en) 2008-10-16
JO2945B1 (en) 2016-03-15
CA2662622A1 (en) 2008-03-20
JP5753924B2 (ja) 2015-07-22
AU2007296499C1 (en) 2013-09-12
ZA200901548B (en) 2010-02-24

Similar Documents

Publication Publication Date Title
AR115939A2 (es) Composición que contiene palmitoil-etanolamida ultra-micronizada
ECSP088239A (es) Composición de liberación de fármaco sostenida
GT200600096A (es) Composicion farmaceutica para el tratamiento del cancer
GT201000008A (es) Agentes citotoxicos que comprenden nuevos derivados de tomaimicina y su uso terapeutico
BR112014016668A8 (pt) composições para cuidados pessoais contendo silicone iônico e agente formador de filme
ECSP109934A (es) Compuesto - 946
CL2011000835A1 (es) Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras.
EA200970274A1 (ru) Способы введения гипогликемических средств с длительным действием
AR089931A1 (es) Composiciones farmaceuticas que contienen dimetilfumarato
CO2018005361A2 (es) Formulaciones inyectables de toxina botulínica y sus métodos de uso que poseen efecto terapéutico o cosmético de larga duración
PE20131324A1 (es) Formulacion subcutanea de anticuerpo anti-her2
ECSP088747A (es) Pirazoles como inhibidores de la 11-beta-hsd1
AR088382A1 (es) Formulaciones de etanercept estabilizadas con xilitol
AR094548A1 (es) Dispersión sólida físicamente estable
GT200700034A (es) Composiciones farmaceuticas de antagonistas del anticuerpo anti-cd40
CL2012001583A1 (es) Preparación oftálmica que comprende: a) povidona yodada, b) un agente refrescante y c) uno o más entre alcanfor, borneol, lubricante, emoliente, antiinflamatorio esteroidal y antinflamatorio no esteroidal; y su uso para el tratamiento y/o profilaxis de un trastorno ocular o una infección.
UY32455A (es) Derivados de aminotetralina, composiciones farmacéuticas que la contienen, y sus usos en terapia
ECSP088973A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
PE20161170A1 (es) Composiciones farmaceuticas que comprenden azd9291
CO6650415A2 (es) Nuevas formas de dosificacion de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidoes de xantina oxidasa
ECSP088240A (es) Composición de trazodona para administración una vez por día
MX2014002697A (es) Imidazopiridazinas sustituidas con amino.
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
UY36542A (es) Formulaciones farmacéuticas para anticuerpos anti-tnf-alfa
UY31780A (es) Fenoxibenzamidas sustituidas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)